Analyst Price Targets — DXCM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 18, 2026 11:37 am | — | Truist Financial | $102.00 | $87.93 | TheFly | DexCom price target raised to $102 from $93 at Truist |
| August 4, 2026 1:17 pm | Steve Silver | Argus Research | $96.00 | $87.00 | TheFly | DexCom price target raised to $96 from $86 at Argus |
| August 3, 2026 11:04 am | — | Canaccord Genuity | $90.00 | $83.45 | TheFly | DexCom price target raised to $90 from $82 at Canaccord |
| August 3, 2026 10:41 am | — | RBC Capital | $90.00 | $83.45 | StreetInsider | DexCom (DXCM) PT Raised to $90 at Canaccord |
| July 31, 2026 12:29 pm | Jayson Bedford | Raymond James | $94.00 | $82.66 | TheFly | DexCom price target raised to $94 from $91 at Raymond James |
| July 31, 2026 11:30 am | Matt O'Brien | Piper Sandler | $95.00 | $74.54 | TheFly | DexCom price target raised to $95 from $88 at Piper Sandler |
| July 31, 2026 11:17 am | — | Robert W. Baird | $105.00 | $74.54 | TheFly | DexCom price target raised to $105 from $80 at Baird |
| July 31, 2026 9:26 am | Marie Thibault | BTIG | $90.00 | $74.54 | StreetInsider | DexCom (DXCM) PT Raised to $90 at BTIG |
| July 31, 2026 9:04 am | Richard Newitter | Truist Financial | $93.00 | $74.54 | StreetInsider | DexCom (DXCM) PT Raised to $93 at Truist Securities |
| July 31, 2026 9:03 am | Jonathan Block | Stifel Nicolaus | $95.00 | $74.54 | StreetInsider | DexCom (DXCM) PT Raised to $95 at Stifel |
Latest News for DXCM
SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief…
DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.